273 related articles for article (PubMed ID: 37410869)
1. Oncogene-like addiction to aneuploidy in human cancers.
Girish V; Lakhani AA; Thompson SL; Scaduto CM; Brown LM; Hagenson RA; Sausville EL; Mendelson BE; Kandikuppa PK; Lukow DA; Yuan ML; Stevens EC; Lee SN; Schukken KM; Akalu SM; Vasudevan A; Zou C; Salovska B; Li W; Smith JC; Taylor AM; Martienssen RA; Liu Y; Sun R; Sheltzer JM
Science; 2023 Aug; 381(6660):eadg4521. PubMed ID: 37410869
[TBL] [Abstract][Full Text] [Related]
2. Oncogene-like addiction to aneuploidy in human cancers.
Girish V; Lakhani AA; Scaduto CM; Thompson SL; Brown LM; Hagenson RA; Sausville EL; Mendelson BE; Lukow DA; Yuan ML; Kandikuppa PK; Stevens EC; Lee SN; Salovska B; Li W; Smith JC; Taylor AM; Martienssen RA; Liu Y; Sun R; Sheltzer JM
bioRxiv; 2023 Jan; ():. PubMed ID: 36711674
[TBL] [Abstract][Full Text] [Related]
3. MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.
Hüllein J; Słabicki M; Rosolowski M; Jethwa A; Habringer S; Tomska K; Kurilov R; Lu J; Scheinost S; Wagener R; Huang Z; Lukas M; Yavorska O; Helfrich H; Scholtysik R; Bonneau K; Tedesco D; Küppers R; Klapper W; Pott C; Stilgenbauer S; Burkhardt B; Löffler M; Trümper LH; Hummel M; Brors B; Zapatka M; Siebert R; Kreuz M; Keller U; Huber W; Zenz T
Cancer Res; 2019 Jun; 79(12):3125-3138. PubMed ID: 31000522
[TBL] [Abstract][Full Text] [Related]
4. Chromosome-level genome editing uncovers aneuploidy addiction in cancer.
O'Brien S; Berger AH
Cell Rep Methods; 2023 Oct; 3(10):100618. PubMed ID: 37820727
[TBL] [Abstract][Full Text] [Related]
5. Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing.
Sayed S; Sidorova OA; Hennig A; Augsburg M; Cortés Vesga CP; Abohawya M; Schmitt LT; Sürün D; Stange DE; Mircetic J; Buchholz F
Cancer Res; 2022 Sep; 82(17):3002-3015. PubMed ID: 35802645
[TBL] [Abstract][Full Text] [Related]
6. Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia.
Sebert M; Gachet S; Leblanc T; Rousseau A; Bluteau O; Kim R; Ben Abdelali R; Sicre de Fontbrune F; Maillard L; Fedronie C; Murigneux V; Bellenger L; Naouar N; Quentin S; Hernandez L; Vasquez N; Da Costa M; Prata PH; Larcher L; de Tersant M; Duchmann M; Raimbault A; Trimoreau F; Fenneteau O; Cuccuini W; Gachard N; Auger N; Tueur G; Blanluet M; Gazin C; Souyri M; Langa Vives F; Mendez-Bermudez A; Lapillonne H; Lengline E; Raffoux E; Fenaux P; Adès L; Forcade E; Jubert C; Domenech C; Strullu M; Bruno B; Buchbinder N; Thomas C; Petit A; Leverger G; Michel G; Cavazzana M; Gluckman E; Bertrand Y; Boissel N; Baruchel A; Dalle JH; Clappier E; Gilson E; Deriano L; Chevret S; Sigaux F; Socié G; Stoppa-Lyonnet D; de Thé H; Antoniewski C; Bluteau D; Peffault de Latour R; Soulier J
Cell Stem Cell; 2023 Feb; 30(2):153-170.e9. PubMed ID: 36736290
[TBL] [Abstract][Full Text] [Related]
7. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
8. Applications of Genome Editing Technology in Research on Chromosome Aneuploidy Disorders.
Akutsu SN; Fujita K; Tomioka K; Miyamoto T; Matsuura S
Cells; 2020 Jan; 9(1):. PubMed ID: 31963583
[TBL] [Abstract][Full Text] [Related]
9. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
[TBL] [Abstract][Full Text] [Related]
10. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
11. MDM4 is a rational target for treating breast cancers with mutant p53.
Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
[TBL] [Abstract][Full Text] [Related]
12. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.
Marcellino BK; Hoffman R; Tripodi J; Lu M; Kosiorek H; Mascarenhas J; Rampal RK; Dueck A; Najfeld V
Blood Adv; 2018 Dec; 2(24):3581-3589. PubMed ID: 30563882
[TBL] [Abstract][Full Text] [Related]
13. Aneuploidy-cancer predisposition syndromes: a new link between the mitotic spindle checkpoint and cancer.
Hanks S; Rahman N
Cell Cycle; 2005 Feb; 4(2):225-7. PubMed ID: 15655355
[TBL] [Abstract][Full Text] [Related]
14. Permission to pass: on the role of p53 as a gatekeeper for aneuploidy.
Marques JF; Kops GJPL
Chromosome Res; 2023 Oct; 31(4):31. PubMed ID: 37864038
[TBL] [Abstract][Full Text] [Related]
15. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.
Wasylishen AR; Lozano G
Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27329033
[TBL] [Abstract][Full Text] [Related]
16. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
17. Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.
Liu T; Zhang H; Yi S; Gu L; Zhou M
Mol Oncol; 2019 May; 13(5):1047-1058. PubMed ID: 30672125
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, causes and impact of TP53-loss phenocopying events in human tumors.
Fito-Lopez B; Salvadores M; Alvarez MM; Supek F
BMC Biol; 2023 Apr; 21(1):92. PubMed ID: 37095494
[TBL] [Abstract][Full Text] [Related]
19. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.
Woodfield SE; Shi Y; Patel RH; Chen Z; Shah AP; Srivastava RK; Whitlock RS; Ibarra AM; Larson SR; Sarabia SF; Badachhape A; Starosolski Z; Ghaghada KB; Sumazin P; Annis DA; López-Terrada D; Vasudevan SA
Sci Rep; 2021 Feb; 11(1):2967. PubMed ID: 33536467
[TBL] [Abstract][Full Text] [Related]
20. p53 Prohibits Propagation of Chromosome Segregation Errors that Produce Structural Aneuploidies.
Soto M; Raaijmakers JA; Bakker B; Spierings DCJ; Lansdorp PM; Foijer F; Medema RH
Cell Rep; 2017 Jun; 19(12):2423-2431. PubMed ID: 28636931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
